Результаты поиска

Conditional deletion of E11/podoplanin in bone protects against load-induced osteoarthritis.

BACKGROUND: Subchondral bone (SCB) thickening is one of the earliest detectable changes in osteoarthritic joints and is considered a potential trigger for subsequent articular cartilage degeneration. In this manuscript, we examine whether disruption to the SCB osteocyte network contributes to the initiation and pathogenesis of osteoarthritis. METHODS: We examined expression patterns of the glycoprotein E11/podoplanin by immunohistochemical labelling in murine, human and canine osteoarthritis models. We also examined the effects of twice-weekly administration of Bortezomib, a proteasome inhibi

Совпадение в полном тексте источника
… Arthritis Rheum. 2008;58:3110–3119. doi: 10.1002/art.23870. 18. Zhu Q, Lin X, Liu X, Hou T, Zhang M, Wang N, et al. Dynamic changes of proteasome and protective effect of bortezomib, a proteasome inhibitor, in mice with acute pancreatitis. … Ann Rheum Dis. 2015;74:1580–1587. doi: 10.1136/annrheumdis-2013-204962. 31. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding Army attacking a unique target. Chem Biol. 2012;19:99–115. doi: 10.1016/j.chembiol.2012.01.003. …

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.

In this concept paper, the authors present a unique and novel protocol to treat autoimmune diseases that may have the potential to reverse autoimmunity. It uses a combination of B cell depletion therapy (BDT), specifically rituximab (RTX) and intravenous immunoglobulin (IVIg), based on a specifically designed protocol (Ahmed Protocol). Twelve infusions of RTX are given in 6-14 months. Once the CD20+ B cells are depleted from the peripheral blood, IVIg is given monthly until B cells repopulation occurs. Six additional cycles are given to end the protocol. During the stages of B cell depletion,

Совпадение в полном тексте источника
… Arthritis Rheum ( 2004 ) 50 : 3580 – 90 . 10.1002/art.20592 15529346 79 Uchida J Lee Y Hasegawa M Liang Y Bradney A Oliver JA Mouse CD20 expression and function . … Arthritis Rheum ( 2006 ) 54 : 613 – 20 . 10.1002/art.21617 16447239 88 Roll P Dörner T Tony HP . Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment . …

Computational approaches in rheumatic diseases - Deciphering complex spatio-temporal cell interactions.

Inflammatory arthritis, including rheumatoid (RA), and psoriatic (PsA) arthritis, are clinically and immunologically heterogeneous diseases with no identified cure. Chronic inflammation of the synovial tissue ushers loss of function of the joint that severely impacts the patient's quality of life, eventually leading to disability and life-threatening comorbidities. The pathogenesis of synovial inflammation is the consequence of compounded immune and stromal cell interactions influenced by genetic and environmental factors. Deciphering the complexity of the synovial cellular landscape has accel…

Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy.

Idiopathic inflammatory myopathy (IIM) is a group of heterogeneous diseases that can affect multiple systems. Currently, it is classified into different subtypes based on myositis-specific antibodies and muscle tissue pathology. These subtypes vary in treatment response and clinical prognosis, with poor treatment outcomes observed in cases of rapidly progressive interstitial lung disease and severe muscle involvement. Despite conventional treatments, there remains a high rate of mortality and disability. The production of B cells and autoantibodies plays a crucial role in the pathogenesis of I

Совпадение в полном тексте источника
… Ann Rheum Dis. 10.1136/ard-2022-223541 36609342 10.1136/ard-2022-223541 17. … Ann Rheum Dis 68(6):836–843. 10.1136/ard.2008.091405 18628284 10.1136/ard.2008.091405 60. …

Терапия сотовой связи для руматоидного артрита.

Химерическая антигенная рецепторная (CAR) клеточная терапия Т произвела революцию в лечении лейкемии, лимфомы и множественных миеломы, реанимировав на поверхности этих клеток антигены CD19 и BCMA. В последнее время появляется все больше свидетельств того, что эти клеточные методы лечения могут также быть направлены против аутоиммунных заболеваний, включая системный волчаньий эритематос, системный склероз, расстройство спектрального спектра нейромиелита, миастения гравис, идиопатический воспалительный миосит, множественный склероз и ревматоидный артрит. На сегодняшний день ten Пациенты с ревмат

Совпадение в аннотации оригинала
Chimeric Antigen Receptor (CAR) T cell therapy has revolutionised the treatment of relapsed/refractory B cell leukaemia, lymphoma and multip … tica spectrum disorder, myasthenia gravis, idiopathic inflammatory myositis, multiple sclerosis and rheumatoid arthritis. To date, ten patients with rheumatoid arthritis have been treated with CAR T cells targeting CD19/CD20 or BCMA antigens on B cells. Nine patients with seropositive disease have shown remarkable responses, including depletion of circu …

Pathogenesis and treatment of Sjogren's syndrome: Review and update.

Sjogren's syndrome (SS) is a chronic autoimmune disease accompanied by multiple lesions. The main manifestations include dryness of the mouth and eyes, along with systemic complications (e.g., pulmonary disease, kidney injury, and lymphoma). In this review, we highlight that IFNs, Th17 cell-related cytokines (IL-17 and IL-23), and B cell-related cytokines (TNF and BAFF) are crucial for the pathogenesis of SS. We also summarize the advances in experimental treatment strategies, including targeting Treg/Th17, mesenchymal stem cell treatment, targeting BAFF, inhibiting JAK pathway, et al. Similar

Совпадение в полном тексте источника
… Ann Rheum Dis (2012) 71(2):295–301. doi: 10.1136/ard.2011.154013 56. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. … Ann Rheum Dis (2019) 78(5):641–7. doi: 10.1136/annrheumdis-2018-214720 130. Smolen J NP, Tahir H, Schulze-Koops H, Li L, Hojnik M, Gellett A, et al. …

Blocking the IL‑6 pathway to treat immune checkpoint inhibitor‑induced inflammatory arthritis (Review).

The incorporation of immune checkpoint inhibitors (ICIs) into cancer treatment has revolutionized oncology, providing marked advantages in managing various types of cancer. Nevertheless, the increasing use of ICIs has led to the emergence of immune‑related side effects, including autoimmune diseases such as inflammatory arthritis. IL‑6 signaling is crucial in the development of inflammatory arthritis and is linked to both the benefits and adverse effects of ICIs. The present review summarizes the latest progress in the IL‑6 pathway in inflammatory arthritis and discusses the therapeutic potent

Совпадение в полном тексте источника
… Ann Rheum Dis. 2017;76:2061–2064. doi: 10.1136/annrheumdis-2017-211560. 37. Abe K, Ishikawa Y, Fujiwara M, Yukawa H, Yanagihara T, Takei S, Arioka H, Kita Y. … Semin Arthritis Rheum. 2019;48:1127–1132. doi: 10.1016/j.semarthrit.2018.10.012. 103. Liapi M, Chatzidionysiou K. POS1356 treatment of immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica. Ann Rheum Dis. 2022;81:1017. doi: 10.1136/annrheumdis-2022-eular.3614. 104. …

Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma.

Although Henoch-Schönlein purpura (HSP) is known to be accompanied by malignancies, cases with hepatobiliary cancer are extremely rare. A 62-year-old man with palpable purpura rapidly extending to both lower legs was admitted to our hospital. He was undergoing follow-up for cirrhosis caused by chronic hepatitis B virus infection and hepatocellular carcinoma (HCC). He had renal dysfunction with hematuria and proteinuria and abdominal pain. Based on the clinical presentation and skin biopsy findings, he was diagnosed with HSP. The administration of steroids resulted in the rapid improvement of t

Совпадение в полном тексте источника
… Semin Arthritis Rheum 29: 360-367, 2000. 10. Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 33: 1114-1121, 1990. 11. Ozen S, Ruperto N, Dillon MJ, et al. … Ann Rheum Dis 65: 936-941, 2006. 12. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65: 1-11, 2013. 13. Rai A, Nast C, Adler S. Henoch-Schönlein purpura nephritis. …

Current progress in CAR-based therapy for kidney disease.

Despite significant breakthroughs in the understanding of immunological and pathophysiological features for immune-mediated kidney diseases, a proportion of patients exhibit poor responses to current therapies or have been categorized as refractory renal disease. Engineered T cells have emerged as a focal point of interest as a potential treatment strategy for kidney diseases. By genetically modifying T cells and arming them with chimeric antigen receptors (CARs), effectively targeting autoreactive immune cells, such as B cells or antibody-secreting plasma cells, has become feasible. The emerg

Совпадение в полном тексте источника
… Ann Rheum Dis . ( 2021 ) 80 : 176–84 . doi: 10.1136/annrheumdis-2020-217844 32998865 14 Orvain C Boulch M Bousso P Allanore Y Avouac J . Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases ? … Ann Rheum Dis . ( 2024 ) 83 : 499 – 507 . doi: 10.1136/ard-2023-224875 38182404 PMC10958264 104 Free ME Bunch DO McGregor JA Jones BE Berg EA Hogan SL . …

Neoplasm related mortality risk in Systemic Sclerosis: a nationwide study.

BackgroundThe higher mortality rates in patients with Systemic sclerosis (SSc) are related to SSc activity, cardiovascular disease, and neoplasms, among other factors. Our objective was to assess the impact of solid organ neoplasms (SON) and hematological neoplasms (HN) on mortality among SSc patients.MethodsA retrospective, observational comparison of SON and HN-related deaths in SSc patients with those in the general Spanish population was conducted using data from the Spanish Hospital Discharge Database. Binary logistic regression was used to analyze the impact of SSc on mortality risk from

Совпадение в полном тексте источника
… Arthritis Rheum. 2005;52:2415–24. 16052585 10.1002/art.21225 10. Pearson JE Risk of cancer in patients with scleroderma Ann Rheum Dis 2003 62 697 9 10.1136/ard.62.8.697 12860720 PMC1754622 Pearson JE. Risk of cancer in patients with scleroderma. … Abu-Shakra M Guillemin F Lee P Cancer in systemic sclerosis Arthritis Rheum 1993 36 460 4 10.1002/art.1780360405 8457221 Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993;36:460–4. 8457221 10.1002/art.1780360405 22. …

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024.

BACKGROUND: Herpes zoster severely impacts patients' quality of life and therapeutic results. This research utilized data from the FDA Adverse Event Reporting System (FAERS) to examine the prevalence and attributes of drug-induced herpes zoster. METHODS: We analyzed FAERS reports about zoster from Q1 2004 to Q3 2024 and developed a list of possible pathogenic agents. Ranked the 30 medicines with the greatest incidence of reported herpes zoster cases. Statistical disproportionality analysis was employed to identify an elevated reporting frequency of herpes zoster linked to a particular medicat

Совпадение в полном тексте источника
… Rheum. Dis. Clin. North Am. 43 ( 1 ), 111 – 121 . 10.1016/j.rdc.2016.09.010 27890168 Chen L.-K. Arai H. Chen L.-Y. Chou M.-Y. Djauzi S. Dong B. ( 2017 ). Looking back to move forward: a twenty-year audit of herpes zoster in asia-pacific . BMC Infect. … Rheum. Dis. 81 ( 1 ), 41 – 47 . 10.1136/annrheumdis-2021-220651 34321218 PMC8762036 Salvetti M. Wray S. Nelles G. Belviso N. Kumar A. Koster T. ( 2024 ). …

CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology.

The acronym for the CCN family was recently revised to represent "cellular communication network". These six, small, cysteine-enriched and e … so supports the involvement of CCN proteins in inflammatory pathologies, such as osteoarthritis and rheumatoid arthritis, as well as in cancers affecting the musculoskeletal system and bone metastasis. These matricellular proteins indeed show involvement in inflammation and cancer, thus representing intriguing therapeutic targets. This review discusses …

Эффективное использование BCMA-нацеливаемого би-специализированного T антитела в реанимации LRP4+ yasthenia gravis.

Myastenia gravis (MG) — аутоиммунное заболевание, вызванное антителом, которое воздействует на нейромышечное соединение. Рефракторный MG, особенно в случаях, связанных с редким антинизкоплотным белком, связанным с рецептором липопротеина 4 (LRP4) Антитела сталкиваются со значительными трудностями в лечении. Teclistamab, биконкретный антитело, нацеленное на антигены созревания клеток B (BCMA) и CD3, перенаправляет Т клетки на плазменные клетки и утверждается для лечения нескольких миелом. Растущий интерес связан с использованием методов лечения на основе Т клеток в клеточных заболеваниях с ауто

Совпадение в полном тексте источника
… Rheum. Dis. 2024;83:1597–1598. doi: 10.1136/ard-2024-226017. 8. Motte J., Sgodzai M., Schneider-Gold C., Steckel N., Mika T., Hegelmaier T., Borie D., Haghikia A., Mougiakakos D., Schroers R., Gold R. … Rheum. Dis. 2025;84:106–114. doi: 10.1136/ard-2024-226142. 16. Mougiakakos D., Meyer E.H., Schett G. CAR T-cells in autoimmunity: game changer or stepping stone? Blood. 2025;145:1841–1849. doi: 10.1182/blood.2024025413. 17. …

Stress Fracture of the Femoral Shaft in Paget's Disease of Bone: A Case Report.

Paget's disease of bone (PDB) is a progressive bone disorder characterized by increased osteoclast-mediated bone resorption and abnormal bone formation. Incomplete atypical femoral fracture, appearing radiographically as a stress fracture at the lateral aspect of the femur, is an uncommon low-trauma fracture frequently seen in association with long-term bisphosphonate therapy. We describe the case of a 61-year-old female patient with PDB who developed a stress fracture at the lateral femoral cortex after 5 doses of intravenous bisphosphonate. The conservative treatment plan included discontinu

Совпадение в полном тексте источника
… ach to diagnosis of stress fractures including bisphosphonate-associated fractures QJM 2014 107 99 105 10.1093/qjmed/hct192 24106312 10 Meléndez LM Llorente I García E SAT0288 atypical femoral fractures after treatment with bisphosphonates and denosumab in inflammatory and senile osteoporosis Ann Rheum … 223 6 10.11005/jbm.2014.21.3.223 25247161 PMC4170086 26 Reid IR Miller P Lyles K Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease N Engl J Med 2005 353 898 908 10.1056/NEJMoa044241 16135834 27 Winfield J Stamp TC Bone and joint symptoms in Paget’s disease Ann Rheum …

Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management.

A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.

Совпадение в полном тексте источника
… Rheum Dis Clin North Am . ( 2003 ) 29 : 239 – 54 . 10.1016/S0889-857X(03)00022-X 12841293 6. Barnes J Mayes MD . Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers . … Ann Rheum Dis . ( 2010 ) 69 : 1809 – 15 . 10.1136/ard.2009.114264 20551155 8. Singh D Parihar AK Patel S Srivastava S Diwan P Singh MR . Scleroderma: an insight into causes, pathogenesis and treatment strategies . …

Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma.

The immune system is strongly linked to the maintenance of healthy bone. Inflammatory cytokines, specifically, are crucial to skeletal homeostasis and any dysregulation can result in detrimental health complications. Interleukins, such as interleukin 6 (IL-6), act as osteoclast differentiation modulators and as such, must be carefully monitored and regulated. IL-6 encourages osteoclastogenesis when bound to progenitors and can cause excessive osteoclastic activity and osteolysis when overly abundant. Numerous bone diseases are tied to IL-6 overexpression, including rheumatoid arthritis, osteop…

Sclerosing diseases of the skin.

Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients' quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality. This review explores the current understanding of the four most prevalent sclerosing skin diseases - localized scleroderma (morphea), systemic sclerosis (SSc), scleromyxedema, and scleredema adultorum of Buschke - as well as sclerotic conditions induced

Совпадение в полном тексте источника
… Ann Rheum Dis. 2013;72(11):1747‐1755. 64. Lescoat A. Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease. J Scleroderma Relat Disord. 2023;8(1):3‐6. 65. Tyndall A, Fistarol S. … Ann Rheum Dis. 2017;76(8):1327‐1339. 68. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655‐2666. 69. Tashkin DP, Roth MD, Clements PJ, et al. …

Expert Perspective: Hematologic Malignancies and Vasculitis.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Ann Rheum Dis 2018 ; 77 ( 5 ): 636 – 643 . 29358285 10.1136/annrheumdis-2017-212649 29 Kouijzer IJE , Mulders‐Manders CM , Bleeker‐Rovers CP , et al. Fever of unknown origin: the value of FDG‐PET/CT . … Semin Arthritis Rheum 2020 ; 50 ( 5 ): 879 – 884 . 32896704 10.1016/j.semarthrit.2020.07.002 63 Mekinian A , Zhao LP , Chevret S , et al. …

Осложнения при беременности и аутоиммунные заболевания у женщин: систематический обзор и метаанализ.

Осложнения во время беременности могут привести к возникновению у женщин аутоиммунных заболеваний. Цель этого обзора заключается в обобщении исследований, посвященных оценке взаимосвязи между осложнениями при беременности и развитием аутоиммунных заболеваний у женщин. МЕТОДЫ: До января были проведены обыски баз данных Medline, CINAHL и Cochrane 2024. Nineteen осложнения беременности и 15 Включены аутоиммунные условия. Заголовок, абстрактный, полный текстопроверка, извлечение данных и оценка качества были проведены two Независимые эксперты. Данные обобщались с использованием описательных и коли

Совпадение в аннотации оригинала
BACKGROUND: Pregnancy complications might lead to the development of autoimmune diseases in women. This review aims to summarise studies eva … 27-2.94), Crohn's disease (n = 1) IRR 1.61 (1.25-2.04), psoriasis (n = 1) IRR 1.33 (1.01-1.71), and rheumatoid arthritis (n = 2) IRR 1.35 (1.09-1.64). Miscarriage associated with subsequent diagnosis of Sjogren syndrome (n = 2) IRR 1.33 (1.06-2.81) and rheumatoid arthritis (n = 4) OR 1.11 (1.04-1.20). Gestational hypertension/preeclampsia was linked wit …

Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential.

BackgroundDespite progress that has been made in the treatment of many immune-mediated inflammatory diseases (IMIDs), there remains a need for improved treatments. Randomised controlled trials (RCTs) provide the highest form of evidence on the effectiveness of a potential new treatment regimen, but they are extremely expensive and time consuming to conduct. Consequently, much focus has been given in recent years to innovative design and analysis methods that could improve the efficiency of RCTs. In this article, we review the current use and future potential of these methods within the context

Совпадение в полном тексте источника
… We restricted our evaluation to clinical trial publications that have appeared since 2018 in any of five high impact factor journals relevant to IMIDs ( New Engl J Med , Lancet , Ann Rheum Dis , Arthritis Rheumatol , J Am Acad Dermatol ). … Ann Rheum Dis. 2020;79(Suppl 1):1464–1465. doi: 10.1136/annrheumdis-2020-eular.1124. 8. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheum. 2014;66:775–782. doi: 10.1002/art.38323. 9. …